Rigel Pharmaceuticals, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
REGNRegeneron Pharmaceuticals, Inc. -0.82%562.422.7%$646.15m
GILDGilead Sciences, Inc. -1.21%58.011.0%$570.64m
AMGNAmgen, Inc. -0.51%215.281.3%$564.14m
VRTXVertex Pharmaceuticals, Inc. -1.21%205.821.9%$527.71m
MRNAModerna, Inc. 3.67%68.150.0%$430.73m
ILMNIllumina, Inc. -0.34%308.653.5%$395.90m
EXASEXACT Sciences Corp. -1.37%125.7720.7%$293.52m
ALXNAlexion Pharmaceuticals, Inc. 1.73%116.842.0%$264.32m
BIIBBiogen, Inc. 0.43%245.321.7%$252.18m
NVAXNovavax, Inc. 0.58%81.8096.5%$239.74m
BNTXBioNTech SE 5.31%81.660.0%$208.68m
SRRKScholar Rock Holding Corp. 3.53%44.960.0%$181.15m
SGENSeagen Inc. -2.63%189.746.0%$141.15m
SRNESorrento Therapeutics, Inc. 0.42%7.121.4%$136.08m
CRSPCRISPR Therapeutics AG -1.21%93.560.6%$121.89m

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.